A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs BL M08D1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
- 16 Jan 2025 Planned initiation date changed from 1 Dec 2024 to 1 Feb 2025.
- 10 Dec 2024 New trial record